Human Genome Sciences, Inc.

The General Hospital Corporation

Massachusetts Institute of Technology

Robert J Melder

Craig A Rosen

Ralph Froman Alderson

Steven M Ruben

Rakesh K Jain

Viktor Roschke

John M Greene

Jing-Shan Hu

D Roxanne Duan

Roxanne Duan

Paolo Netti

Lance L Munn

Gabriel Helmlinger

Hera Lichtenbeld-Dubois

Gerald C Koenig

The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides.

Methods of treating an injury to, or disorder of, the eye involving photoreceptor proliferation by administering VEGF2 antibodies

Use of vascular endothelial growth factor to treat photoreceptor cells

The present invention relates to a novel human protein called Fibroblast Growth Factor 11, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

Antibodies against fibroblast growth factor 11

The present invention relates to a novel human protein called Fibroblast Growth Factor 15, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein.

Polynucleotides encoding fibroblast growth factor 15

Cells in a matrix or in the matrix in a vessel are grown to form a multicellular aggregate. Pressure is exerted on the growing cells by the matrix or the matrix together with the vessel due to growing cellular mass displacing the matrix. A value representing pressure exerted on the cells is calculated and the pressure is modulated to control growth of the multicellular aggregate, or to produce a multicellular aggregate of a pre-selected size or a pre-selected size and shape. Matrices include agarose, alginate and collagen gels, and the pressure exerted on the cells can be non-isotropic. The cells may be tumor cells, or liver, pancreatic, brain, skin, bone or muscle cells, and cell growth can be in vitro or in vivo. When collagen forms the matrix, the matrix may contain glycosaminoglycan.

Modulation of multicellular aggregates by pressure from growth in a matrix

A method of treating a condition involving vascular adhesion of cytotoxic white cells by (a) identifying an animal suspected of having a condition involving vascular adhesion of cytotoxic white cells and (b) administering to the animal an amount of bFGF sufficient to decrease cell surface expression of ICAM-I or VCAM-I on endothelial cells, thereby reducing adhesion of cytotoxic white cells to vascular endothelium.

Therapeutic use of bFGF to treat conditions involving adhesion of

Growing community of inventors

Gaithersburg, MD, United States of America

Robert J Melder